Establishment of a 8 Immune-Related LncRNA Signature for Predicting the Prognosis of Soft Tissue Sarcoma

Yuhang Liu
Zhongnan Hospital of Wuhan University

Changjiang Liu
Zhongnan Hospital of Wuhan University

Aixi Yu (✉ yuaixi@whu.edu.cn)
Zhongnan Hospital of Wuhan University

Research Article

Keywords: long noncoding RNA, prognostic model, bioinformatics analysis, soft tissue sarcoma, biomarker, immune infiltrate

Posted Date: September 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-882267/v1

License: ☑️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background**: Soft tissue sarcoma is relatively rare and highly heterogeneous, which brings great difficulties to treatment. Long non-coding RNA acts a vital role in the occurrence and progression of soft tissue sarcoma, especially in the tumor-related immune process, which has become a hot spot of current research. Therefore, we are committed to developing lncRNA markers related to immunity to promote the treatment and prognosis of patients with soft tissue sarcoma.

**Methods**: Based on the TCGA-SARC and GTEx data set, we screened out 8 prognostic-related immune lncRNAs and constructed a nomogram, which was verified in the test set. Furthermore, immune infiltration analysis was carried out on patients of high and low risk.

**Results**: Based on the results of Pearson's correlation coefficient, we obtained 859 immune-related lncRNAs. After difference analysis, we finally determined 54 different lncRNAs. Univariate and multivariate cox regression analysis finally determined 8 immune-related lncRNAs to construct prognostic models and nomograms to predict the prognosis of STS patients. The above results have been verified in external data sets, indicating that this model has good predictive ability. Gene Set Enrichment Analysis and ESTIMATE analysis showed obviously differences exist in the immune infiltration status and immune cell subtypes of high- and low-risk patients.

**Conclusion**: We constructed an immune-related lncRNA pattern to predict the survival status of soft tissue sarcoma patients.

1 Introduction

Soft tissue sarcoma is a kind of tumor with very high rarity and heterogeneity. It contains at least 100 different histological and molecular subtypes with different clinical features.[1]. Because of these characteristics, soft tissue sarcomas are often difficult to diagnose, their treatment options are limited, and the results are mediocre.[2]. In view of the actual situation of STS treatment, it is imperative to find a more accurate prognostic assessment method.

More and more studies have shown that immune response is crucial in tumor progression, as well as in soft tissue sarcoma. Recent studies have confirmed that there is a large amount of immune heterogeneity between subtypes of soft tissue sarcoma, and clinical trial reports have shown that they have a clear response to immunotherapy. [3]. The combined use of immunotherapy and immune checkpoint inhibitors has shown a clear effect on certain types of soft tissue sarcoma.[4].

Many researches have demonstrated that lncRNAs related to immune have a significant impact on tumors.[5]. However, there are relatively few studies on immune-related lncRNA in soft tissue sarcoma. Therefore, here, for the first time, we have established a 8 immune-related lncRNA signature to predict the prognosis of STS patients, which is been verified accurately in the validation set. We performed GSEA analysis and immune correlation analysis on the high and low risk groups identified by the multivariate
cox analysis. In conclusion, this 8-DEIRLs can predict the prognosis of STS patients very well, and may contribute to the precise treatment and immunotherapy of STS patients.

2. Materials And Methods

2.1 Collection of Sample and Data

We downloaded RNA expression profiles with corresponding clinical features from the UCSC Xena website (https://xena.ucsc.edu/) in the TCGA-SARC and GTEx databases. The GTEx database contains RNA transcriptome data of 54 normal tissue samples from healthy individuals. We obtained the RNA sequencing data of the muscle and adipose tissue from the GTEx database and used it as a control for comparison. There are 263 tumor samples and 2 normal samples in TCGA-SARC, and 911 normal samples in GTEx. A total of 1176 samples are used as the training set. The GSE21050 gene sequence data, which contained 310 sarcoma samples, was identified as an external validation.

2.2 Immune-related LncRNA

First, we isolated the expression data of LncRNA from the TCGA-SARC genome data. Secondly, we obtained the transcriptome data of genes related to immune, based on following gene set, IMMUNE_RESPONSE and IMMUNE_SYSTEM_PROCESS. Then we performed Pearson correlation coefficient analysis on the immune gene matrix and LncRNA expression matrix, and obtained immune-related LncRNA expression data, based on R > 0.4 and P < 0.001. With the help of the ‘limma’ package, we performed a differential analysis of these LncRNAs. Based on |logFC| > 0.05 and adjust p < 0.05, we obtained 54 LncRNAs and proceeded to the next excavation.

2.3 Identification of immune-related LncRNA related to OS and establishment of prognostic signatures

We performed univariate cox regression analysis, LASSO regression analysis, and multivariate cox regression analysis, and screened out 8 prognostic-related LncRNAs. The risk score was calculated as follows: riskScore = Σ\[i=0]^{n} \beta_i \ast G_i

\( \beta_i \) is defined as the coefficient of LncRNA \( i \) of the multivariate cox regression analysis; \( G_i \) presents level of each LncRNA. STS patients were separated into the high-risk group and the low-risk group on account of median risk score. To assess the accuracy of results, we analyzed the data in the test set at the same level. To assess the availability of our signature, we conducted overall survival analysis to evaluate the OS differences in high-risk and low-risk patients. ROC curves at 3 and 5 years were also generated to evaluate the credibility and accuracy of the signature. In the next step, we performed univariate cox and multivariate cox analysis on the risk score and patient clinical information to construct a nomogram.
2.4 The Gene Set Enrichment Analysis

To investigate the differences in gene function between high- and low-risk STS patients, we conducted a GSEA analysis, including the following gene set: IMMUNE_RESPONSE and IMMUNE_SYSTEM_PROCESS.

2.5 Analysis of immune infiltration in high risk and low risk STS patients

We analyzed the relationship between 8 DEIRLs risk score and immune microenvironment in STS patients, including ESTIMATEScore, TumorPurity, ImmuneScore, StromalScore.

3. Results

3.1 Screening of the differentially expressed immune-related LncRNAs (DEIRLs)

We isolated 13,832 LncRNA expression matrices from the TCGA-SARC database, and then we downloaded gene set related to immune (IMMUNE_RESPONSE and IMMUNE_SYSTEM_PROCESS) from MSigDB, and abstract the SARC immune-related gene expression matrix, a total of 332. Based on the criteria of R > 0.4 and P < 0.001, pearson correlation coefficient analysis was performed between expression matrix of this genes and LncRNA matrix, then 859 immune-related LncRNAs were determined. Furthermore, we performed a differential analysis of these LncRNAs in R. Via ‘limma’ package, |logFC| > 0.05 and adjust p < 0.05 was used as the selection criterion, and finally 54 DEIRLs were obtained. The flow chart of this research is shown in Fig. 1. The heatmap and volcano map of these DEIRLs are shown in Fig. 2.

3.2 Risk signature construction

Using the method of univariate cox regression analysis, we initially obtained 14 DEIRLs. After LASSO regression and multivariate cox regression analysis, 8 DEIRLs related to prognosis were finally determined. COX and LASSO analysis results are shown in Fig. 3.

Risk score = \( (X_{C5orf56} \times -0.8317) + (X_{LINC00294} \times 0.28715) + (X_{LINC01023} \times -0.2395) + (X_{PCOLCE-AS1} \times 0.804617) + (X_{LINC00944} \times 0.3021) + (X_{LINC01140} \times 0.230992) + (X_{SERTAD4-AS1} \times -0.21676) + (X_{THUMPD3-AS1} \times 1.040621) \).

On account of the median risk score, patients with STS were separated into two groups, high-risk and low risk. We drew expression heatmaps, risk distribution plots and survival status profiles of the 8 identified DEIRLs, and compared the survival difference between the two groups both in training set and test set. (Fig. 4A,4C,4E,4G). Similar differences were also obtained in the test group, which verified the prognostic
As shown in Fig. 5A and 5B, the 8 DEIRLs characteristic can satisfactorily predict the survival status of STS patients, with AUC: 0.784 (test set: 0.585).

3.3 Evaluation of the IncRNA signature

The results of univariate and multivariate independent prognostic analysis showed that 8 DEIRLs risk characteristics were obviously related to the survival status of STS, with p-value < 0.001. (Fig. 6A and 6B). Analysis of multiple ROC curves showed that risk score signature had the largest AUC area. (Fig. 6E). The size of AUC represents the prognostic efficiency of the 8 DEIRLs model. The larger the area, the better the predictive effect of the patient's prognosis. In addition, based on the “timeROC” (version 0.4) package in R, curves were plotted to evaluate the predictive value. (Fig. 5C and 5D). Our results showed that the 8 DEIRLs prognostic model could well predict the 3- and 5-year survival rate (AUC 0.76 and 0.765). These results demonstrated that the accuracy and sensitivity was excellent. Based on multiple Cox regression, we conducted a prognostic nomogram to predict the 1-year, 3-year and 5-year survival possibility. (Fig. 7A). Furthermore, calibration plots of 3- and 5-survival prediction were used to assess the predictive ability of nomogram, as shown in Fig. 7B-D. The calibration curve showed that the nomogram had a high consistency between the survival state prediction results and the actual results in the training and test set.

3.4 Gene set enrichment analysis (GSEA)

We used GSEA software to analyze the differences of immune gene set in high-risk and low-risk patient groups, and the results showed that a higher degree of immune gene enrichment exists in low-risk population. In addition, KEGG pathway analysis and GO analysis are also used to further explore risk-related pathways and genes. Figure 8.

3.5 Analysis of immune infiltration between high- and low-risk patients

Using the ESTIMATE algorithm, we studied the differences of tumor immune status in high- and low-risk patient groups. Figure 9A. Compared to the low-risk patients, the high-risk patients had higher tumor purity. However, the StromalScore ImmuneScore, ESTIMATEScore were all lower. (Fig. 9B-D). Given the above results, we also explored the correlation between risk groups and immune cell subtypes. The results showed that CD4+ cells, Macrophage cells, Neutrophil cells were related to risk groups (P < 0.05). Figure 10-A, B, C.

4. Discussion

In the contemporary era of the development of precision medicine, tailoring a treatment plan for the clinicopathological and molecular characteristics of each patient’s tumor is extremely important for the
treatment of the patient. [6, 7]. The doctor's preoperative evaluation, postoperative prediction, and follow-up have a profound impact on the quality of life of cancer patients.[8, 9].

Doctors are exploring targeted precision therapies for specific histological subtypes and genetic mutations of each STS patient. There is an urgent need to link the patient's transcriptome information with the best treatment strategy.[10]. Some recent studies have made the genomic characterization of subtypes of soft tissue sarcoma more precise and discovered some prognostic-related molecular markers.[11].

Long non-coding RNA (lncRNA) has multiple functions in regulating gene expression at both transcription and translation levels, and more and more studies have found that lncRNA is closely related to tumor immunity.[12]. With the development of bioinformatics, more and more immune-related lncRNAs have been mined to construct tumor prognosis models.[13],[14],[15]. In this study, we constructed for the first time a lncRNA model including 8 immune-related lncRNAs, and verified the accuracy of this model as a marker for the survival status of soft tissue sarcoma. First, we analyzed the transcriptome data of TCGA SARC and obtained the lncRNA co-expressed with immune genes. After univariate and multivariate Cox regression analysis, we finally determined 8 immune-related lncRNAs: C5orf56, LINC00294, LINC01023, PCOLCE-AS1, LINC00944, LINC01140, SERTAD4-AS1, THUMPD3-AS1. Next, by comparing with other clinical characteristics, the score determined by 8 DEIRLs has the largest ROC value, indicating that this model has an excellent prognostic predictive ability for STS patients. The risk score and clinical information are combined to construct a nomogram to predict the 1, 3, and 5-year survival rate of patients, and the corresponding calibration chart shows that this nomogram has relatively high accuracy. We used GSEA to explore the differences in gene function between high- and low-risk populations, and the results showed that high-risk patients had relatively low levels of immune gene enrichment. The ESTIMATE algorithm showed that there were significant differences in immuneScore, tumor purity, StromalScore, ESTIMATEScore, between high- and low-risk patients. And, this 8 DEIRLs model related to 3 immune cell subtypes: CD4 + cells, Macrophage cells, Neutrophil cells.

GSEA analysis showed that these lncRNAs were enriched in the pathways of "KEGG_SPLICEOSOME", "KEGG_RNA_POLYMERASE", "KEGG_PYRIMIDINE_METABOLISM", "KEGG_RNA_DEGRADATION" and "KEGG_CELL_CYCLE". Recent genome analysis has shown that many of the molecular changes observed in cancer result from mutations in the splicing process. Understanding the link between tumor cell biology and splicing regulation is essential for studying pathogenesis and treatment methods.[16]. Mutations in RNA polymerase regulatory factors are one of the most important regulators of cell malignant differentiation.[17]. Xiuxing Wang er al have found that targeting pyrimidine synthesis pathway can improve the therapeutic effect of glioblastoma stem cells on molecular biology.[18]. RNA degradation plays an important role in tumor cells. For example, Jing-Ting Chiou et al found that degradation of HuR mRNA caused by autophagy induced down-regulation of survivin and MCL1 protein levels in leukemia cells that is treated with YM155.[19]. The cell cycle of cancer cells is dysregulated, leading to uncontrolled growth of tumor cells.[20]. ESTIMATE algorithm and TIMER database analysis show that this model is
closely related to tumor immune infiltration and immune cell subtypes, which may provide potential targets for immunotherapy of soft tissue sarcoma.

There have been some studies on the role of these DEIRLs in tumor cells. Xiaokun Zhou et al. found that overexpression of LINC00294 inhibited the growth of glioma cells and induces apoptosis. [21]. Linc01023 can inhibit the growth and metastasis of glioma cells by regulating the IGF1R/AKT pathway. [22]. Pamela R de Santiago et al. discovered that LINC00944 regulated the level of ADAR1 in breast cancer cells, and the expression of LINC00944 was positively correlated with T lymphocyte infiltration. [23]. Knockdown of LINC01140 can inhibit the growth and metastasis of glioma cells through miR-199a-3p. [24]. THUMPD3-AS1 affects the proliferation of NSCLC cells by regulating the level of ONECUT2, so it can be used as a prognostic-related marker and a potential therapeutic target. [25].

As we know, this is the first time that an immune-related IncRNA model has been constructed to predict the prognosis of patients with soft tissue sarcoma, and the immune infiltration related to the model has been explored. The GTEx database makes up for the shortcomings of the lack of normal samples in the TCGA database. However, this work has some limitations: First of all, some important clinical features of patients in the TCGA database are not sufficiently detailed, such as tumor stage information, which may affect the treatment and prognosis of STS patients. Second, it is necessary to further determine the functional correlation between the expression levels of these 8 DEIRLs and the immunophenotype in soft tissue sarcoma at the cellular level. Finally, in order to ensure the predictive performance of the nomogram, more independent external queues should be analyzed on the basis of our model construction method.

5. Conclusion

All in all, we have constructed a new type of immune-related IncRNA signature to predict the prognosis of patients with soft tissue sarcoma. In addition, we also found the high- and low-risk patients had different immune infiltration status based on the risk score. These findings may provide new insights into the prognosis assessment of STS patients, and may provide new ideas for the immunotherapy of STS.

Declarations

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the UCSC Xena repository (https://xena.ucsc.edu/), and GEO database (https://www.ncbi.nlm.nih.gov/geo/).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Information
Contributions

Yuhang Liu designed the study. Yuhang Liu and Changjiang Liu generated the figures and table. Yuhang Liu conducted data processing. Yuhang Liu and Changjiang Liu wrote the manuscript. Aixi Yu supervised the research.

Affiliations

Department of Trauma and Microsurgery Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan430072, China.

Yuhang Liu, Changjiang Liu, Aixi Yu

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Disclosure Statement

All authors have no relevant financial or non-financial competing interests.

Funding

This work was supported by the Hubei Province Scientific and Technical Innovation Key Project (No.2019ACA136).

Acknowledgments

None

References

1. Adriana C Gamboa, Alessandro Gronchi, Kenneth Cardona. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020 May;70(3):200-229. doi: 10.3322/caac.21605. Epub 2020 Apr 10.

2. Megan Meyer, Mahesh Seetharam. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9.

3. Mayanne M T Zhu, Elahe Shenasa, Torsten O Nielsen. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. Cancer Treat Rev. 2020
4. Eiji Nakata¹, Tomohiro Fujiwara¹, Toshiyuki Kunisada¹, Tastuo Ito², Shota Takihira¹, Toshifumi Ozaki. Immunotherapy for sarcomas. Jpn J Clin Oncol. 2021 Apr 1;51(4):523-537. doi: 10.1093/jjco/hyab005.

5. Lei Ding, Shengdi Lu, Yanli Li. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathol Oncol Res. 2020 Apr;26(2):651-663. doi: 10.1007/s12253-019-00735-9. Epub 2019 Nov 20.

6. Sven Rottenberg, Carmen Disler, Paola Perego. Nat Rev Cancer. 2021 Jan;21(1):37-50. doi: 10.1038/s41568-020-00308-y. Epub 2020 Oct 30.

7. Xiao Zhu, Shi Li, Bairui Xu, Hui Luo. Cancer evolution: A means by which tumors evadetreatment. Biomed Pharmacother. 2021 Jan;133:111016. doi: 10.1016/j.biopha.2020.111016. Epub 2020 Nov 24.

8. R Casolino, C Braconi, G Malleo, S Paiella, C Bassi, M Milella, S B Dreyer, F E M Froeling, D K Chang, A V Biankin, T Golan. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol. 2021 Feb;32(2):183-196. doi: 10.1016/j.annonc.2020.11.013. Epub 2020 Nov 26.

9. Linda Tran, Jin-Fen Xiao, Neeraj Agarwal, Jason E Duex, Dan Theodorescu. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021 Feb;21(2):104-121. doi: 10.1038/s41568-020-00313-1. Epub 2020 Dec 2.

10. Kenji Nakano, Shunji Takahashi. Precision Medicine in Soft Tissue Sarcoma Treatment. Cancers (Basel). 2020 Jan 16;12(1):221. doi: 10.3390/cancers12010221.

11. Thomas Gp Grünewald, Marta Alonso, Sofia Avnet et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020 Nov 6;12(11):e11131. doi: 10.15252/emmm.201911131. Epub 2020 Oct 13.

12. Ming-Chun Jiang, Jiao-Jiao Ni, Wen-Yu Cui, Bo-Ya Wang, Wei Zhuo. Emerging roles of IncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019 Jul 1;9(7):1354-1366. eCollection 2019.

13. Mengqin Yuan, Yanqing Wang, Qinqian Sun, Shiyi Liuet al. Identification of a Nine Immune-Related IncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma. Biomed Res Int. 2021 Jan5;2021:9798231.doi:10.1155/2021/9798231. eCollection 2021.

14. Jinhui Liu, Jie Mei, Yichun Wang, Xucheng Chen, Jiadong Pan, Laigen Tong, Yan Zhang. Development of a novel immune-related IncRNA signature as a prognostic classifier for endometrial carcinoma. Int J Biol Sci. 2021 Jan 1;17(2):448-459. doi: 10.7150/ijbs.51207. eCollection 2021.

15. Lan Mu, Ke Ding, Ranran Tu, Wei Yang. Identification of 4 immune cells and a 5-IncRNA risk signature with prognosis for early-stage lung adenocarcinoma. J Transl Med. 2021 Mar 26;19(1):127.doi: 10.1186/s12967-021-02800-x.

16. Patricia P Coltri, Maria G P Dos Santos, Guilherme H G da Silva. Splicing and cancer: Challenges and opportunities. Wiley Interdiscip Rev RNA. 2019 May;10(3):e1527.doi: 10.1002/wrna.1527. Epub 2019 Feb 17.
17. Megan J Bywater, Richard B Pearson, Grant A McArthur, Ross D Hannan. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer. 2013 May;13(5):299-314. doi: 10.1038/nrc3496.

18. Jing-Ting Chiou, Yuan-Chin Lee, Chia-Hui Huang, Yi-Jun Shi, Liang-Jun Wang, Long-Sen Chang. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. Toxicol Appl Pharmacol. 2020 Jan 15;387:114857. doi:10.1016/j.taap.2019.114857. Epub 2019 Dec 16.

19. Gary K Schwartz, Manish A Shah. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005 Dec 20;23(36):9408-21.doi: 10.1200/JCO.2005.01.5594.

20. Xiaokun Zhou, Liang Lv, Zhongyi Zhang, Shuyang Wei, Tong Zheng. LINC00294 negatively modulates cell proliferation in glioma through a neurofilament medium-mediated pathway via interacting with miR-1278. J Gene Med. 2020 Oct;22(10):e3235.doi: 10.1002/jgm.3235. Epub 2020 Jun 18.

21. Mingjun Yu, Shijia Yu, Wei Gong, Duo Chen, Junhong Guan, Yunhui L. Knockdown of linc01023 restrains glioma proliferation, migration and invasion by regulating IGF-1R/AKT pathway. J Cancer. 2019 Jun 2;10(13):2961-2968.doi: 10.7150/jca.31004. eCollection 2019.

22. Pamela R de Santiago, Alejandro Blanco, Fernanda Morales, Katherine Marcelain, Olivier Harismendy, Marcela Sjöberg Herrera, Ricardo Armisén. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sci. 2021 Mar 1;268:118956. doi:10.1016/j.lfs.2020.118956. Epub 2020 Dec 29.

23. Yanchao Xin, Wuzhong Zhang, Chongchong Mao, Jianxin Li, Xianzhi Liu, Junbo Zhao, Junfeng Xue, Junqing Li, Yonglu Ren. LncRNA LINC01140 Inhibits Glioma Cell Migration and Invasion via Modulation of miR-199a-3p/ZHX1 Axis. Onco Targets Ther. 2020 Feb 28;13:1833-1844.doi:10.2147/OTT.S230895. eCollection 2020.

24. Jia Hu, Youfang Chen, Xiaodong Li, Huikai Miao, Rongzhen Li, Dongni Chen, Zhesheng Wen. THUMPD3-AS1 Is Correlated With Non-Small Cell Lung Cancer And Regulates Self-Renewal Through miR-543 And ONECUT2. Onco Targets Ther. 2019 Nov 19;12:9849-9860.doi:10.2147/OTT.S227995. eCollection 2019.

Figures
Figure 1

Flowchart of construction and validation of 8 DEIRLs signature and nomogram.
Figure 2

Differently expressed immune-related lncRNAs in TCGA SARC database based on the $|\log 2\text{FC}| \geq 0.5$ and $p<0.05$. (A) Heatmap of DEIRLs. (B) Volcano plot of DEIRLs. FC, fold change. Color images are available online.
Figure 3

Feature selection using the Univariate Cox analysis, Lasso regression and Multivariate Cox analysis. (A) Forest map of DEIRLs associated with STS survival, univariate Cox regression, p<0.05. (B) LASSO coefficient spectrum of 14 DEIRLs. (C) On account of 1000 cross-validation for tuning parameter selection via LASSO. (D) the forest map of 8 DEIRLs analyzed by Multivariate Cox analysis.
Figure 4

Risk signature development. Survival analysis of the training (A), test (B). Differences in gene expression level, risk distribution, and survival status between in the high and low-risk groups, training set (C,E,G), test set (D,F,H).
Figure 5

ROC of 11-lncRNA model in the training (A), test (B).
Figure 6

Assessment of the 8-DEIRLs signature. Result of univariate Cox analysis. (A). Result of multivariate Cox analysis. (B). Result of multiple ROC analyses (E). AUC in ROC analysis for risk signature at the 3- and 5-year survival time in train set (C), test set (D).
Figure 7

Construction and assessment of a novel nomogram incorporating the IncRNA signature with clinical factors. Nomograms to predict OS of patients with STS. (A). Calibration curves of nomogram with 1-year (B), 3-year (C), and 5-year (D).
Figure 8

Gene set enrichment analysis of 8-DEIRLs signature. ‘h’ stands for high-risk groups and ‘l’ stands for low-risk groups.
Figure 9

the Result of ESTIMATE algorithm based on the risk group.
Figure 10

the 3 immune cell subtypes associated with the 8-DEIRLs signature.